IP Library Granted Patent US 11,352,606
Granted Patent B2
US 11,352,606 · App. 15/115,718 · Granted Jun 7, 2022

Low oxygen tension enhances endothelial fate of human pluripotent stem cells

Inventors: Sharon Gerecht (Baltimore, MD); Sravanti Kusuma (Baltimore, MD)
Assignee: The Johns Hopkins University
C12N5/069A61K35/44A61K35/545C12N2500/02C12N2501/15C12N2501/165C12N2506/02C12N2506/45C12N2533/54
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,352,606
App. No.
15/115,718
Granted
Jun 7, 2022
Kind
B2
Abstract

Low oxygen tension is a critical regulator of the developing or regenerating vasculature. The present invention is based on the determination that low oxygen tension during early stages of early vascular cell (EVC) derivation induces endothelial commitment and maturation of pluripotent stem cells. Inhibition of reactive oxygen species generation during the early stages of differentiation abrogates the endothelial inductive effects of the low oxygen environments. Methods of generating various types of cells from pluripotent stem cells (PSCs) are described, as well as compositions and methods of use thereof. In particular, generation of EVCs, bicellular vascular populations, early endothelial cells (ECs) and pericytes via culture in a low oxygen environment is described.

Claims (18)

1. A method of generating early vascular cells (EVCs) comprising endothelial cells (ECs) and pericytes, comprising:

a) culturing pluripotent stem cells (PSCs) under hypoxic conditions of about 1-5% oxygen on a first two-dimensional culture substrate in a monolayer in a first growth medium for a time suitable to induce differentiation of the PSCs to generate EVCs;

b) differentiating the cells of a) under hypoxic conditions of about 1-5% oxygen on a second culture substrate in a second growth medium comprising a transforming growth factor-β(TGF-β) inhibitor and a vascular endothelial growth factor (VEGF) for a time suitable to induce differentiation of the cells of b) to generate a population of ECs expressing vascular endothelial cadherin and pericytes expressing platelet-derived growth factor receptor beta and neural/glial antigen 2 (NG2), thereby generating EVCs comprising ECs and pericytes.

2. The method of claim 1 , wherein the PSCs are human pluripotent stem cells (hPSCs) that are cultured on a two-dimensional substrate selected from a petri dish, a roller bottle, a flask or a three-dimensional substrate.

3. The method of claim 1 , wherein hypoxic conditions are about 5% oxygen.

4. The method of claim 1 , wherein the first two-dimensional culture substrate is selected from the group consisting of type I collagen, type IV collagen and fibronectin.

5. The method of claim 1 , wherein the ECs are surrounded by the pericytes.

6. The method of claim 1 , wherein the TGF-β inhibitor is SB431542.

7. The method of claim 1 , wherein the second growth medium comprises from about 1 to 25 μM TGF-β inhibitor.

8. The method of claim 1 , wherein the second growth medium comprises 10 μM SB431542.

9. The method of claim 1 , wherein the VEGF is VEGF-A.

10. The method of claim 1 , wherein the second growth medium comprises from about 10 to 80 ng/ml VEGF.

11. The method of claim 1 , wherein the second growth medium comprises 50 ng/ml VEGF.

12. The method of claim 1 , wherein the time suitable to induce differentiation in step a) is about 2 to 12 days.

13. The method of claim 1 , wherein the time suitable to induce differentiation in step b) is about 2 to 12 days.

14. A method of generating early vascular cells (EVCs) comprising endothelial cells (ECs) and pericytes, comprising:

a) culturing pluripotent stem cells (PSCs) under hypoxic conditions of about 1-5% oxygen on a first two-dimensional culture substrate in a monolayer in a first growth medium suitable to induce differentiation of the PSCs to generate EVCs;

b) differentiating the cells of a) under hypoxic conditions of about 1-5% oxygen on a second culture substrate in a second growth medium consisting essentially of a transforming growth factor-β(TGF-β) inhibitor and vascular endothelial growth factor (VEGF), thereby inducing differentiation of the cells of a) into a population of ECs expressing vascular endothelial cadherin and pericytes expressing platelet-derived growth factor receptor beta and neural/glial antigen 2 (NG2), thereby generating EVCs comprising ECs and pericytes.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2019
From: GERECHT, SHARON; KUSUMA, SRAVANTI
To: THE JOHNS HOPKINS UNIVERSITY
Reel/Frame 048461/0540 →
CONFIRMATORY LICENSE Recorded Feb 21, 2018
From: JOHNS HOPKINS UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045388/0892 →
Continuity (2)
Provisional Application 61938062 · Feb 10, 2014
Related Publication 20170009204A1 · Jan 12, 2017